These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065 [TBL] [Abstract][Full Text] [Related]
43. Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review. Caya CA; Boikos C; Desai S; Quach C Vaccine; 2015 Mar; 33(11):1302-12. PubMed ID: 25660650 [TBL] [Abstract][Full Text] [Related]
44. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan. Jiang Y; Yang X; Taniguchi K; Petigara T; Abe M J Med Econ; 2018 Jul; 21(7):687-697. PubMed ID: 29723081 [TBL] [Abstract][Full Text] [Related]
45. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450 [TBL] [Abstract][Full Text] [Related]
46. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047 [TBL] [Abstract][Full Text] [Related]
47. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727 [TBL] [Abstract][Full Text] [Related]
48. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis. Ruiz-Aragón J; Márquez Peláez S; Molina-Linde JM; Grande-Tejada AM Vaccine; 2013 Nov; 31(46):5349-58. PubMed ID: 24055349 [TBL] [Abstract][Full Text] [Related]
49. Comparison of pneumococcal vaccination response in children with sickle cell disease: HbSS and HbSC. Le Ng X; Alikhan M; Stark JM; Mosquera RA; Shahrukh Hashmi S; Gonzales T; Brown DL; Nguyen TT; Yadav A Allergol Immunopathol (Madr); 2019; 47(6):564-569. PubMed ID: 31164233 [TBL] [Abstract][Full Text] [Related]
50. Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults. Gaillat J Med Mal Infect; 2013 Jun; 43(6):215-21. PubMed ID: 23769155 [TBL] [Abstract][Full Text] [Related]
51. Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right? Papadatou I; Spoulou V Clin Vaccine Immunol; 2016 May; 23(5):388-395. PubMed ID: 27009210 [TBL] [Abstract][Full Text] [Related]
52. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study. Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101 [TBL] [Abstract][Full Text] [Related]
53. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655 [TBL] [Abstract][Full Text] [Related]
55. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings. Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806 [TBL] [Abstract][Full Text] [Related]
56. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732 [TBL] [Abstract][Full Text] [Related]
57. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan. Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA; Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524 [TBL] [Abstract][Full Text] [Related]
58. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial. van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA Pediatr Infect Dis J; 2016 Jul; 35(7):e206-19. PubMed ID: 27097348 [TBL] [Abstract][Full Text] [Related]
59. Pharmacists as providers: targeting pneumococcal vaccinations to high risk populations. Taitel M; Cohen E; Duncan I; Pegus C Vaccine; 2011 Oct; 29(45):8073-6. PubMed ID: 21864625 [TBL] [Abstract][Full Text] [Related]
60. Safety of revaccination with pneumococcal polysaccharide vaccine. Jackson LA; Benson P; Sneller VP; Butler JC; Thompson RS; Chen RT; Lewis LS; Carlone G; DeStefano F; Holder P; Lezhava T; Williams WW JAMA; 1999 Jan; 281(3):243-8. PubMed ID: 9918479 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]